<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-144-72</article-id>
<article-id pub-id-type="doi">10.26800/LV-144-3-4-2</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Original article</subject></subj-group>
</article-categories>
<title-group>
<article-title>Kirur&#x0161;ko lije&#x010D;enje gigantskih bazocelularnih karcinoma lica: na&#x0161;e iskustvo</article-title>
<trans-title-group xml:lang="en">
<trans-title>Surgical treatment of giant basal cell carcinoma of the face: our experience</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0860-6923</contrib-id><name><surname>Kova&#x010D;i&#x0107;</surname><given-names>Ivan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kova&#x010D;i&#x0107;</surname><given-names>Marijan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kera</surname><given-names>Marija</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ta&#x010D;igin</surname><given-names>Tamara</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<aff id="aff1"><label>1</label><institution>Slu&#x017E;ba za kirurgiju, Op&#x0107;a bolnica Zadar</institution>, <addr-line>Zadar</addr-line></aff>
<aff id="aff2"><label>2</label><institution>Odjel za otorinolaringologiju, Op&#x0107;a bolnica Zadar</institution>, <addr-line>Zadar</addr-line></aff>
<aff id="aff3"><label>3</label><institution>Odjel za otorinolaringologiju, Op&#x0107;a bolnica Pula</institution>, <addr-line>Pula</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Prim. Marijan Kova&#x010D;i&#x0107;, dr. med., <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-0860-6923">https://orcid.org/0000-0003-0860-6923</ext-link> Obala Kneza Branimira 2E, 23000 Zadar, e-po&#x0161;ta: <email xlink:href="mar.kova@yahoo.com">mar.kova@yahoo.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>03</month><year>2022</year></pub-date>
<volume>144</volume>
<issue>3-4</issue>
<fpage>72</fpage>
<lpage>78</lpage>
<permissions>
<copyright-year>2022</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<p>Gigantski bazocelularni karcinom (GBCC) rijetki je tumor ko&#x017E;e veli&#x010D;ine 5 i vi&#x0161;e cm. Glavnim &#x010D;imbenicima njegova nastanka smatraju se zapostavljanje konvencionalnoga bazocelularnog karcinoma (BCC) od strane bolesnika i/ili biolo&#x0161;ka agresivnost tumora. Svojim sporim infiltrativnim rastom naru&#x0161;avaju strukturni i funkcionalni integritet zahva&#x0107;enog podru&#x010D;ja. Za njegovo lije&#x010D;enje, bez obzira na lokalizaciju, ne postoje usvojene smjernice i jo&#x0161; uvijek predstavlja terapeutski problem. U ovom radu analizirali smo karakteristike bolesnika i tumora kao i njegov odgovor na kirur&#x0161;ko lije&#x010D;enje. Od ukupnog broja bolesnika s BCC-om glave i vrata u periodu od 11 godina izdvojili smo njih 24 s GBCC-om lica. Svi su bili tre&#x0107;e &#x017E;ivotne dobi u rasponu od 65 do 86 godina, ve&#x0107;inom siroma&#x0161;ni, skloni alkoholu i depresiji. Veli&#x010D;ina i povr&#x0161;ina tumora u sredi&#x0161;njem dijelu lica bila je ne&#x0161;to manja nego u postrani&#x010D;nom dijelu. Prevladavao je mu&#x0161;ki spol u omjeru 1,4:1. Sve smo bolesnike podvrgnuli kirur&#x0161;kom lije&#x010D;enju odstranjenja tumora s histolo&#x0161;ki slobodnim rubovima te je istovremeno izvr&#x0161;ena i rekonstrukcija nastalog defekta. Za vrijeme pra&#x0107;enja od prosje&#x010D;no 36 mjeseci nismo imali povrat bolesti niti pojavu metastaza, a funkcionalni i estetski rezultat bio je dobar. Histolo&#x0161;ki su u ve&#x0107;ini slu&#x010D;ajeva bili neagresivni podtipovi tumora (nodularni), a vrijeme trajanja bolesti jest prosje&#x010D;no 5,9 godina. Za nastajanje GBCC-a kod na&#x0161;ih bolesnika uglavnom teretimo njihov indolentan stav prema bolesti. GBCC se mo&#x017E;e uspje&#x0161;no kirur&#x0161;ki lije&#x010D;iti i u tako zahtjevnom podru&#x010D;ju kao &#x0161;to je lice i bez obzira na starosnu dob bolesnika.</p>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Giant basal cell carcinoma (GBCC) is a rare skin tumor with the longest diameter greater than five cm.The main factors for its occurrence are considered to be the neglect of conventional basal cell carcinoma (BCC) by patients and the biological aggressiveness of the tumor. With its slow infiltrative growth it disrupts the structural and functional integrity of the affected area. There are no guidelines for its treatment regardless of localization and it still poses a therapeutic problem.In this study, we analyzed patient and tumor characteristics and response to GBCC surgical treatment. Of the total number of patients with BCC over a period of 11 years we isolated 24 cases with GBCC. All patients were in the third age range, from 65 to 86 years old, mostly poor, prone to alcohol and depression.The size and area of the tumor in the central part of the face were slightly smaller than in the lateral part. Male gender predominated (1.4:1). All patients underwent surgical resection of the tumor with histologically confirmed free margins, as the only method of treatment. Reconstruction of the resulting defect was performed in the same procedure . During the follow-up of 36 months on average no recurrence of the disease or metastasis in any of the patients was observed. Histological processing also defined the subtype of these tumors. Most were non-aggressive, nodular form tumors. Due to the duration of the disease, an average of 5.9 years, we believe that the greatest responsibility for the development of this subtype of BCC is the indolent attitude of the patient. Facial GBCC can be successfully treated surgically in such a demanding area as the face, and regardless of the patient&#x2019;s age.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori BAZOCELULARNI KARCINOM &#x2013; kirurgija, patologija</kwd><kwd>TUMORI KO&#x017D;E &#x2013; kirurgija, patologija</kwd><kwd>TUMORI LICA &#x2013; kirurgija, patologija</kwd><kwd>REKONSTRUKCIJSKI KIRUR&#x0160;KI ZAHVATI &#x2013; metode</kwd><kwd>ISHOD LIJE&#x010C;ENJA</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>CARCINOMA, BASAL CELL &#x2013; pathology, surgery</kwd><kwd>SKIN NEOPLASMS &#x2013; pathology, surgery</kwd><kwd>FACIAL NEOPLASMS -&#x2013; pathology, surgery</kwd><kwd>RECONSTRUCTIVE SURGICAL PROCEDURES &#x2013; methods</kwd><kwd>TREATMENT OUTCOME</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Maligni tumori ko&#x017E;e predstavljaju hetreogenu skupinu tumora. Mogu nastati bilo od kojega njenog sastavnog dijela. Naj&#x010D;e&#x0161;&#x0107;i je bazocelularni karcinom (BCC) koji je podrijetlom iz pluripotentnih stanica bazalnog sloja epidermisa i vanjske ovojnice korijena dlake. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) Predominantno se javlja na lokacijama ko&#x017E;e izlo&#x017E;ene suncu i kod starijih osoba. Njegova je incidencija u stalnom porastu diljem svijeta. Razlozi su jednostavni, &#x017E;ivotni vijek ljudi je du&#x017E;i, izlo&#x017E;enost suncu sve ve&#x0107;a, a dijagnostika sve bolja. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Obi&#x010D;no se pojavljuje kao bezbolna nodularna ili ulcerozna promjena ko&#x017E;e i ima izrazito niski metastatski potencijal. Ova vrsta raka ko&#x017E;e u ranoj je fazi lako izlje&#x010D;iva, ali svako du&#x017E;e odlaganje ili neadekvatno lije&#x010D;enje mo&#x017E;e rezultirati njegovim &#x0161;irenjem u dublje slojeve ko&#x017E;e i okolno tkivo. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) Kada tako zanemareni BCC dosegne ili prema&#x0161;i veli&#x010D;inu promjera od 5 cm, nazivamo ga gigantskim bazocelularnim karcinomom (GBCC). Ovaj se podtip BCC-a vrlo rijetko javlja. Njegova frekvencija je mala, oko 0,5% svih BCC-a. Za njegovo lije&#x010D;enje, bez obzira na lokalizaciju, ne postoje usvojenje smjernice i jo&#x0161; uvijek predstavlja terapeutski problem. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) U ovom radu iznosimo na&#x0161;a iskustva kirur&#x0161;kog lije&#x010D;enja GBCC-a lica i neposredne rekonstrukcije nastalog defekta u predstavljenoj grupi od 24 bolesnika. Predmet analize bile su karakteristike bolesnika, tumora i izbor metode rekonstrukcije. Na&#x0161; pristup lije&#x010D;enja bio je usmjeren na potpuno uklanjanje tumora i ponovnu uspostavu naru&#x0161;ene funkcije i estetskog izgleda bolesnika, &#x0161;to je umnogome pobolj&#x0161;alo njihovu kvalitetu &#x017E;ivota.</p>
<sec sec-type="other1">
<title>Bolesnici i metode</title>
<p>U ovoj deskriptivnoj retrospektivnoj studiji istra&#x017E;ili smo pojavnost GBCC-a u na&#x0161;ih bolesnika, koje smo kirur&#x0161;ki lije&#x010D;ili zbog BCC-a ko&#x017E;e glave i vrata, u razdoblju od sije&#x010D;nja 2009. do prosinca 2019. godine. Izdvojili smo ukupno 24 bolesnika kojima je najdu&#x017E;i promjer BCC-a bio ve&#x0107;i od 5 cm. Razvrstali smo ispitanike po spolu, dobi, mjestu stanovanja, obiteljskom statusu, higijensko-ekonomskom nivou, prisutnosti alkoholizma, depresije i drugog komorbiditeta. Daljnja razdioba je izvr&#x0161;ena prema karakteristikama tumora, njegovoj veli&#x010D;ini, smje&#x0161;taju, prisutnosti metastaze te du&#x017E;ini vremena javljanja. Podijelili smo tumore na rekurentne i tumore <italic>de novo</italic>. S obzirom na operacijski zahvat izvr&#x0161;ili smo razdiobu prema primijenjenoj anesteziji, metodi rekonstrukcije, komplikacijama, trajanju bolni&#x010D;kog lije&#x010D;enja kao i histolo&#x0161;kim obilje&#x017E;jima. Tijekom pra&#x0107;enja bolesnika promatrana je pojava recidiva, kvaliteta &#x017E;ivota i socijalna integracija. Pojedine demografske i tumorske karakteristike analizirali smo statisti&#x010D;kim postupkom (c (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) test) ispitivanja prisutnosti razlika na razini zna&#x010D;ajnosti (p&lt;0,05).</p>
</sec>
<sec sec-type="other2">
<title>Rezultati</title>
<p>Od ukupno 4.216 bolesnika kirur&#x0161;ki lije&#x010D;enih zbog BCC-a ko&#x017E;e glave i vrata, GBCC su imali njih 24 (0,57%). Svi tumori su bili u podru&#x010D;ju lica i niti jedan bolesnik nije imao genodermatozu. Mu&#x0161;ki spol (14 bolesnika) bio je vi&#x0161;e zastupljen od &#x017E;ena (10 bolesnica). Dobni raspon se kretao od 65 do 86 godina, prosje&#x010D;ne vrijednosti od 76,7 godina. S obzirom na mjesto stanovanja, u urbanoj sredini je &#x017E;ivjelo njih 9, a u ruralnoj preostalih 15 bolesnika. Obiteljsku i/ili dru&#x0161;tvenu skrb imalo je pola bolesnika, a druga polovina njih su &#x017E;ivjeli sami. Higijensko-ekonomski nivo je bio nizak u 17 bolesnika, a preostalih 7 su imali srednje kvalitetne uvjete &#x017E;ivota. Svi bolesnici su imali jednu ili vi&#x0161;e komorbidnih bolesti. Nijedan bolesnik nije bio lije&#x010D;eni alkoholi&#x010D;ar, ali konzumiranje ve&#x0107;e koli&#x010D;ine alkohola navelo je 11 mu&#x0161;karaca i 9 &#x017E;ena, dok je dodatno depresivni sindrom, potvr&#x0111;en psihijatrijskim nalazima, imalo 4 bolesnika (<xref ref-type="fig" rid="f1">Figure 1</xref>). Mjesto primarnog sijela u podru&#x010D;ju prednjeg lica, &#x010D;ela, periorbitalne regije, nosa, nazolabijalne brazde bilo je kod 9 bolesnika, a postrani&#x010D;ni dio lica, obraz, u&#x0161;ka i sljepoo&#x010D;na regija u preostalih 15 bolesnika (<xref ref-type="fig" rid="f2">Figure 2 A, B, C</xref>, <xref ref-type="fig" rid="f3">Figure 3 A, B, C</xref>). Svi su imali promjer ve&#x0107;i od 5 cm, prosje&#x010D;no 7,9 cm. Raspon se kretao od 12 cm do 5,2 cm. Povr&#x0161;ine tumora postrani&#x010D;nog dijela lica bile su zna&#x010D;ajno ve&#x0107;e od povr&#x0161;ina prednjeg dijela lica. Ni u jednog bolesnika klini&#x010D;ki ni ultrazvu&#x010D;no nije zabilje&#x017E;ena prisutnost metastaza. Vremenski razmak od pojave tumora do kirur&#x0161;kog zahvata, po izjavi bolesnika ili njegove pratnje, varirao je u rasponu od 2 do 7 godina. Zna&#x010D;ajna ve&#x0107;ina njih je imala tumor <italic>de novo</italic> (75%), a samo kod &#x0161;estoro GBCC je bio posljedica povrata bolesti (<xref ref-type="table" rid="t1">Table 1</xref>). Svi bolesnici su samo kirur&#x0161;ki lije&#x010D;eni. U op&#x0107;oj anesteziji u&#x010D;inili smo 16 zahvata, a preostalih 8 u lokalnoj anesteziji. Za rekonstrukciju koristili smo ko&#x017E;ni slobodni transplantat u 2 bolesnika, jedan ili dva ko&#x017E;na lokalna re&#x017E;nja lica i vrata u 13, a u preostalih 9 bolesnika rekonstrukciju smo izveli s fasciokutanim i/ili s mi&#x0161;i&#x0107;nokutanim re&#x017E;njevima u istom aktu. Kod svih bolesnika postignut je dobar estetski izgled i uspostavljena zadovoljavaju&#x0107;a naru&#x0161;ena funkcija (nos, periorbitalna regija, usna &#x0161;upljina). Histolo&#x0161;kom analizom je potvr&#x0111;ena dijagnoza GBCC-a, a resekcijski rubovi su svi bili slobodni. Nodularni podtip je bio naj&#x010D;e&#x0161;&#x0107;i kod 12 (50%) bolesnika, mikronodularni u 3 (12,5%), a bazoskvamozni (metatipi&#x010D;ni) u 3 (12,5%) bolesnika. Kod preostalih 6 (25%) bolesnika podtip nije bio odre&#x0111;en. Trajanje bolni&#x010D;kog lije&#x010D;enja prosje&#x010D;no je bilo 7,9 dana, ne&#x0161;to dulje kod bolesnica. Od ranih komplikacija imali smo upalu mjesta rekonstrukcije u 3 (12,5%) bolesnika, a rubnu nekrozu manjeg obujma u 6 (25%) bolesnika (<xref ref-type="fig" rid="f4">Figure 4</xref>). Nije zabilje&#x017E;ena komplikacija donatorskog mjesta, niti je izvr&#x0161;en drugi operacijski zahvat. Tijekom pra&#x0107;enja u rasponu od 17 do 84 mjeseca (prosje&#x010D;no 36 mjeseci) nismo zabilje&#x017E;ili povrat bolesti, a kvaliteta &#x017E;ivota i socijalna integracija promatrana od strane &#x010D;lanova obitelji i dru&#x0161;tvenih slu&#x017E;bi bila je pobolj&#x0161;ana u svim slu&#x010D;ajevima. Analiza bolesnika zasebno razvrstanih po spolu nije pokazala zna&#x010D;ajnu razliku niti jedne promatrane karakteristike, uklju&#x010D;uju&#x0107;i i ishod lije&#x010D;enja.</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>Demographic characteristics of patients Ekonomski status / Economic status: D, dobar; S, siroma&#x0161;an; G, good; P, poverty</p></caption><graphic xlink:href="LV-144-72-f1"></graphic></fig>
<fig id="f2" position="float" fig-type="figure"><label>Figure 2</label><caption><p>A 70-year-old woman with GBCC of medial canthus extending to the upper and lower eyelids and to the nasal area (A). Defect formed after tumor ablation (B). Final appearance of the patient after reconstruction with local flaps (C).</p></caption><graphic xlink:href="LV-144-72-f2"></graphic></fig>
<fig id="f3" position="float" fig-type="figure"><label>Figure 3</label><caption><p>A 72-year-old woman with ulcerative GBCC of the face which penetrated into the oral cavity, parotid gland and cartilaginous part of the ear canal (A). The resulting complete cheek defect after tumor ablation (B). The result of reconstruction after 36 months of follow-up. Reconstruction was performed with a combination of two regional flaps of the island musculocutaneous flaps (C).</p></caption><graphic xlink:href="LV-144-72-f3"></graphic></fig>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Tumour characteristics</title>
</caption>
<table frame="hsides" rules="groups">
<col width="10.09%"/>
<col width="8.87%"/>
<col width="8.28%"/>
<col width="8.87%"/>
<col width="11.24%"/>
<col width="8.88%"/>
<col width="11.24%"/>
<col width="10.06%"/>
<col width="10.64%"/>
<col width="11.83%"/>
<thead>
<tr>
<th rowspan="2" valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Spol / Sex</th>
<th valign="middle" colspan="2" align="left" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Tumor / Tumour</th>
<th valign="middle" colspan="2" align="left" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Lokalizacija na licu / Localization on the face</th>
<th valign="middle" colspan="2" align="left" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Povr&#x0161;ina tumora / Tumour area</th>
<th rowspan="2" valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Prosje&#x010D;na povr&#x0161;ina / Average area<break/>cm<sup>2</sup></th>
<th rowspan="2" valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Metastaza / Metastasis<break/>Da&#x2013;Yes / Ne&#x2013;No</th>
<th rowspan="2" valign="middle" align="left" scope="col" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">Trajanje bolesti (god.) / Disease duration<break/>(year)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Novi / De novo</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Recidiv / Relapse</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Sprijeda / Frontal</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Postrani&#x010D;no / Lateral</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Sprijeda / Frontal<break/>cm<sup>2</sup></td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Postrani&#x010D;no / Lateral<break/>cm<sup>2</sup></td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">M / M<break/>n=14</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">10</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">25,5</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">56,2</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">42,6</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">0/14</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">5,2</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">F / &#x017D;<break/>n=10</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">8</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">2</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">4</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">6</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">21,8</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">53,1</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">45,3</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1/9</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">6,9</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Ukupno / Total<break/>n=24</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">18</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">6</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">9</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">15</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">24,3</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">54,6</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">43,7</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">1/23</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">5,9</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">P&lt;0,05</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Da / Yes</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Ne / No</td>
<td valign="middle" colspan="2" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Da / Yes</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">Ne / No</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">&#x2014;</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">&#x2014;</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>Rekonstrukcija: K, ko&#x017E;ni slobodni transplantat; L, lokalni re&#x017E;anj; R, regionalni re&#x017E;anj; Reconstruction: F, free skin graft; L, local skin flap; R, regional skin flap</p>
<p>Histolo&#x0161;ki tip: A, neagresivan; B, agresivan; C, nije odre&#x0111;en; Histological type: A, non-aggressive; B, aggressive; C, not specified</p>
</table-wrap-foot></table-wrap>
<fig id="f4" position="float" fig-type="figure"><label>Figure 4</label><caption><p>Operative and postoperative characteristics of the procedure and histological analysis</p></caption><graphic xlink:href="LV-144-72-f4"></graphic></fig>
</sec>
<sec sec-type="other3">
<title>Rasprava</title>
<p>BCC je naj&#x010D;e&#x0161;&#x0107;a lokalna zlo&#x0107;udna lezija ko&#x017E;e. Njegova incidencija je &#x0161;irom svijeta u porastu. Za njegov nastanak odgovorno je vi&#x0161;e &#x010D;imbenika. Osim genetske predispozicije i pojedinih kemijskih kancerogena najve&#x0107;i utjecaj ima ultravioletno zra&#x010D;enje sun&#x010D;ane svjetlosti. Obi&#x010D;no se javlja u starijih odraslih osoba i to u podru&#x010D;ju glave i vrata, &#x010D;ak do 85% svih slu&#x010D;ajeva. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Njegov rast je spor i mogu&#x0107;nost metastaziranja minimalna. Najpovoljnije standardno lije&#x010D;enje jest &#x0161;iroka kirur&#x0161;ka ekscizija. Svako zanemarivanje njegove prisutnosti i odugovla&#x010D;enje po&#x010D;etka lije&#x010D;enja mo&#x017E;e dovesti do rasta tumora velikih dimenzija. Kada njegov promjer dosegne ili prema&#x0161;i 5 cm, &#x0161;to predstavlja leziju T3 u TNM klasifikaciji, nazivamo ga GBCC. Drugi &#x010D;imbenici nastanka ovog podtipa BCC-a jo&#x0161; uvijek izazivaju proturje&#x010D;nost, kao &#x0161;to su histolo&#x0161;ka agresivnost tumora, izlo&#x017E;enost zra&#x010D;enju, pojavnost tumora nakon prethodnog lije&#x010D;enja ili promjena imunolo&#x0161;kog statusa doma&#x0107;ina. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>&#x2013;<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>) Pojavnost GBCC-a u 21. stolje&#x0107;u je rijetka, ali je i mogu&#x0107;a. Incidencija u prethodnim radovima kre&#x0107;e se oko 0,5% od svih BCC-a, &#x0161;to je podudarno i s na&#x0161;om studijom. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Anatomska razdioba ovog tumora je razli&#x010D;ita. Kod nekih autora GBCC se predominantno javlja na trupu i ekstremitetima, a u nekih u podru&#x010D;ju glave i vrata, sli&#x010D;no kao i konvencionalni BCC. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) Zaccali, et al. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) navode 22% GBCC-a lica od ukupno analiziranog 91 slu&#x010D;aja iz literature. S obzirom na to da je lice izrazito eksponirano podru&#x010D;je i ne mo&#x017E;e se prekriti odje&#x0107;om, ovaj udio i nije tako mali. Razlog je svakako ignorantski stav bolesnika prema ko&#x017E;noj leziji. Uobi&#x010D;ajeno je rano otkrivanje i najmanje ko&#x017E;ne lezije na licu koja u pravilu potakne doma&#x0107;ina na kori&#x0161;tenje medicinske pomo&#x0107;i. Kod na&#x0161;ih bolesnika prosje&#x010D;no vrijeme prisutnosti bolesti iznosilo je dugih 5,9 godina. Iako razlozi mogu biti i vi&#x0161;estruki, smatramo da je spori rast tumora, odsutnost bola i ve&#x0107;eg ispada funkcije doprinijelo zanemarivanju bolesti. Bolesnici su se postupno navikli na promijenjeni izgled. To potkrjepljujemo i razlogom dolaska na&#x0161;ih bolesnika na lije&#x010D;enje. Kod ve&#x0107;ine njih to je bilo krvarenje i neugodan miris kao posljedica nekroze i upale tumora, a ne svjesna &#x017E;elja za lije&#x010D;enjem. U manjem broju su hospitalizirani zbog akutnog pogor&#x0161;anja zdravlja ili egzacerbacije kroni&#x010D;nih bolesti te su sekundarno tretirani radi ovog tipa tumora. Uglavnom su to starije osobe. (<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) Prosje&#x010D;na dobna starost na&#x0161;ih bolesnika bila je ve&#x0107;a od 76 godina, &#x0161;to je vi&#x0161;e od dobi bolesnika u drugim radovima koji su obi&#x010D;no u sedmom desetlje&#x0107;u &#x017E;ivota. (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r5"><italic>5</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) No, obolijevaju od ove bolesti i mla&#x0111;e osobe. Tako Lackey, et al. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>) navode slu&#x010D;aj ovog tumora kod osobe stare samo 43 godine, a prosjek starosti grupe iznosio je 57 godina. Stopa incidencije GBCC-a po spolu nije izrazito razli&#x010D;ita. Dok primjerice Wollina, et al. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>) imaju zna&#x010D;ajno ve&#x0107;i broj &#x017E;ena, Archontaki, et al. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) nagla&#x0161;avaju prevlast mu&#x0161;karaca, sli&#x010D;no kao i u na&#x0161;oj studiji. Obi&#x010D;no su to siroma&#x0161;ni ljudi koji &#x017E;ive u lo&#x0161;im higijenskim uvjetima s te&#x0161;ko dostupnom zdravstvenom njegom. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Kod na&#x0161;ih bolesnika tako&#x0111;er je bilo nagla&#x0161;eno siroma&#x0161;tvo, ali im je zdravstvena njega bila lako dostupna u ve&#x0107;ini slu&#x010D;ajeva. Stoga smo mi&#x0161;ljenja da je glavni razlog izbjegavanja lije&#x010D;enja fizi&#x010D;ka i psihi&#x010D;ka invalidnost bolesnika, udru&#x017E;ena sa strahom od dijagnoze i lije&#x010D;enja. Nezainteresirana obitelj, prijatelji ili dru&#x0161;tveni radnici tako&#x0111;er snose dio odgovornosti za nastanak ovog tipa tumora. Kroni&#x010D;ni alkoholizam tako&#x0111;er se povezuje s razvojem GBCC-a. (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) U na&#x0161;oj grupi, udru&#x017E;en s depresijom, bio je prisutan u vi&#x0161;e od 80% bolesnika. Zna&#x010D;ajno manji udio alkoholizma zabilje&#x017E;ili su Archontaki, et al. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>), svega 7,8% (4 bolesnika), &#x0161;to dalje ostavlja otvorenom raspravu o razlozima ignorantskog stava bolesnika prema ovoj bolesti. Kako navode Rossi, et al. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>) i Rendle (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>), GBCC je u oko dvije tre&#x0107;ine bolesnika povratni tumor, &#x0161;to tako&#x0111;er mo&#x017E;e biti razlogom zanemarivanja lije&#x010D;enja. Razo&#x010D;aranost bolesnika u raniji postupak i nevjera u povoljan ishod lije&#x010D;enja svakako su va&#x017E;ni &#x010D;imbenici koji mogu doprinijeti odgodi lije&#x010D;enja. Kod na&#x0161;ih bolesnika nije bio takav slu&#x010D;aj, ve&#x0107; sasvim suprotno. Tumori <italic>de novo</italic> su bili u ve&#x0107;ini, stoga negativno iskustvo nije bilo razlog izbjegavanja lije&#x010D;enja. Sli&#x010D;an rezultat navode Oudit, et al. (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>)</p>
<p>U nastanku GBCC-a svakako sudjeluju agresivni histolo&#x0161;ki podtipovi BCC-a (mikronodularni, morfeoformni, bazoskvamozni). (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r16"><italic>16</italic></xref>) U na&#x0161;em radu agresivnu formu, mikronodularnu i bazeoskvamoznu imalo je 6 bolesnika, svi s povratnim tumorom. Gotovo pola tumora bili su histolo&#x0161;ki neagresivni nodularnog podtipa, kao &#x0161;to navode Archontaki, et al. (<xref ref-type="bibr" rid="r8"><italic>8</italic></xref>) Ovakav rezultat vi&#x0161;e implicira va&#x017E;nost histolo&#x0161;kog podtipa za pojavu povrata bolesti kod konvencionalnog BCC-a, a ne za uzro&#x010D;nost GBCC-a. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>&#x2013;<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Bez obzira na podtipove, svi GBCC-i imaju sposobnost invazije u susjedne slojeve ko&#x017E;e i okolnog tkiva. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Naru&#x0161;avaju strukturni i funkcionalni integritet zahva&#x0107;enog podru&#x010D;ja. Ako je suditi po rezultatima Wetzel, et al. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) koji su dobili zna&#x010D;ajno ve&#x0107;u dubinu invazije agresivnih podtipova BCC-a od neagresivnih, mo&#x017E;emo o&#x010D;ekivati istovjetnu situaciju i kod GBCC-a, no dosada nije bilo takvih ispitivanja, niti smo mi to promatrali. Dubina invazije i agresivnost histolo&#x0161;kih podtipova pogoduje razvoju metastaza kod BCC-a. Iznimno su rijetke, sa stopom incidencije 0,002% &#x2013; 0,5%, i proporcionalne su s veli&#x010D;inom tumora. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>, <xref ref-type="bibr" rid="r20"><italic>20</italic></xref>) Snow, et al. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) navode da su 80% metastaza BCC-a od tumora kojima je promjer ve&#x0107;i od 5 cm. Za njihovo nastajanje odgovorni su i drugi &#x010D;imbenici: pojava lezije u podru&#x010D;ju ko&#x017E;e izlo&#x017E;enom radioterapiji, imunosupresija, lokalni recidivi bolesti i njihovo dugo vrijeme evaluacije. Naj&#x010D;e&#x0161;&#x0107;e su to GBCC-i u podru&#x010D;ju sredi&#x0161;njeg lica i u&#x0161;ke s prisutnom perivaskularnom i perineuralnom invazijom, histolo&#x0161;ki skleroziraju&#x0107;i, mikronodularni i bazoskvamozni tip karcinoma. Metastaze nastaju limfogenim i hematogenim &#x0161;irenjem bolesti te zahva&#x0107;aju naj&#x010D;e&#x0161;&#x0107;e regionalne limfne &#x010D;vorove i plu&#x0107;a. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>, <xref ref-type="bibr" rid="r2"><italic>2</italic></xref>, <xref ref-type="bibr" rid="r8"><italic>8</italic></xref>, <xref ref-type="bibr" rid="r9"><italic>9</italic></xref>, <xref ref-type="bibr" rid="r22"><italic>22</italic></xref>) Prisutnost metastaza u dosada&#x0161;njim radovima je nekonzistentno zastupljena. (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>&#x2013;<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) Bitno utje&#x010D;u na prognozu bolesti i rezultat lije&#x010D;enja. U na&#x0161;oj seriji bolesnika imali smo samo u jednom slu&#x010D;aju metastazu i to u podru&#x010D;ju dou&#x0161;ne &#x017E;lijezde u neposrednoj blizini tumora. Klini&#x010D;ki nije bila manifestna, nego je otkrivena tijekom histolo&#x0161;ke obrade uz dokazanu odsutnost direktne ekstenzije ko&#x017E;ne lezije u podru&#x010D;je intraparotidnog limfnog &#x010D;vora. Radilo se o bazoskvamoznom podtipu BCC-a koji se odlikuje iznimno agresivnim biolo&#x0161;kim pona&#x0161;anjem, dubokom invazijom, infiltracijom tkiva i visokim postotkom recidiva nakon primarnoga kirur&#x0161;kog zahvata. (<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>, <xref ref-type="bibr" rid="r24"><italic>24</italic></xref>) Zbog ove naravi bazoskvamoznog karcinoma Johnson, et al. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>) izdvajaju ga kao poseban entitet i nazivaju ga &#x201C;vukom u ov&#x010D;joj ko&#x017E;i&#x201D;. Ostali slu&#x010D;ajevi su bili bez metastaza, iako su tumori bili zna&#x010D;ajne veli&#x010D;ine i sijela u podru&#x010D;ju sredi&#x0161;njeg dijela lica koje se odlikuje tankom ko&#x017E;om i dobrom vaskularizacijom, &#x0161;to pogoduje razvoju metastaza. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>&#x2013;<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>)</p>
<p>Najpovoljnije lije&#x010D;enje GBCC-a kao i svih BCC-a jest kirur&#x0161;ka ekscizija sa slobodnim resekcijskim rubovima. Obi&#x010D;no to uklju&#x010D;uje 1 cm ruba normalnog tkiva oko tumora. Kirur&#x0161;ko lije&#x010D;enje se pokazalo najbr&#x017E;im i najprakti&#x010D;nijim. Njegov uspjeh je ovisan o veli&#x010D;ini, lokalizaciji tumora, njegovoj resektabilnosti, vje&#x0161;tini kirur&#x0161;kog tima i dakako o samoj dobi bolesnika. U ve&#x0107;ini slu&#x010D;ajeva su to starije osobe s komorbiditetima, &#x0161;to ograni&#x010D;ava vrijeme operacije, utje&#x010D;e na izbor operacijskih metoda i naru&#x0161;ava zacjeljivanje rane. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>&#x2013;<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>) Vo&#x0111;eni ovim uvjetima, a zbog &#x0161;to boljeg podno&#x0161;enja zahvata kod na&#x0161;ih bolesnika koristili smo ve&#x0107;inom standardne tehnike rotacije i transpozicije lokalnih re&#x017E;njeva. Slobodni ko&#x017E;ni transplantat kao najjednostavniju metodu pokrivanja defekta koristili smo kod dvaju bolesnika. Opse&#x017E;ne destrukcije lica nadoknadili smo s jednim ili dva regionalna re&#x017E;nja. Odsutnost ozbiljnih komplikacija i upotreba sekundarnih zahvata potvrda nam je ispravnosti odluke o izboru metoda rekonstrukcije. Ni u jednog bolesnika nismo zabilje&#x017E;ili pojavu rezidualnog tumora, kao ni povrat bolesti za vrijeme pra&#x0107;enja. Odsutnost kasnih komplikacija, atrofije, kontrakture ili kolapsa re&#x017E;nja dodatna su nam potvrda da se i GBCC karcinom mo&#x017E;e uspje&#x0161;no lije&#x010D;iti u tako zahtjevnom podru&#x010D;ju kao &#x0161;to je lice, bez obzira na starosnu dob bolesnika.</p>
</sec>
<sec sec-type="other4">
<title>Zaklju&#x010D;ak</title>
<p>Ovdje smo prikazali grupu bolesnika s GBCC-om lica koje smo lije&#x010D;ili radikalnom kirur&#x0161;kom ekscizijom tumora. Rekonstrukcija zaostalog defekta u&#x010D;injena je u istom aktu, primjenom metoda prilago&#x0111;enih komorbidnim bolestima i dobnoj starosti bolesnika. Ovakvim pristupom lije&#x010D;enja GBCC-a lica uspjeli smo odstraniti tumor kod svih bolesnika bez ve&#x0107;ih komplikacija, uz dobar funkcionalni i estetski rezultat. Zbog visokog rizika ponovne pojave bolesti i o&#x010D;uvanja postignutog rezultata potrebna je dobra onkolo&#x0161;ka kontrola. Pojavnost ovog tipa tumora mo&#x017E;e se dodatno smanjiti primjenom rane ekscizije i histolo&#x0161;ke kontrole BCC-a.</p>
</sec>
</body>
<back>
<ref-list>
<title>LITERATURA</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogers</surname><given-names>HW</given-names></name><name><surname>Weinstock</surname><given-names>MA</given-names></name><name><surname>Feldman</surname><given-names>SR</given-names></name><name><surname>Coldiron</surname><given-names>BM</given-names></name></person-group>. <article-title>Incidence Estimate of nonmelanoma skin cancer (Keratinocyte carcinoma) in the U.S. population 2012.</article-title> <source>JAMA Dermatol</source>. <year>2015</year>;<volume>151</volume>:<fpage>1081</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1001/jamadermatol.2015.1187</pub-id><pub-id pub-id-type="pmid">25928283</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>WQ</given-names></name><name><surname>Weinstock</surname><given-names>MA</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Qureshi</surname><given-names>AA</given-names></name></person-group>. <article-title>History of severe sunburn and risk of skin cancer among women and man in 2 prospective cohort studies.</article-title> <source>Am J Epidemiol</source>. <year>2016</year>;<volume>183</volume>:<fpage>824</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwv282</pub-id><pub-id pub-id-type="pmid">27045074</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purnell</surname><given-names>JC</given-names></name><name><surname>Gardner</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Shalin</surname><given-names>SC</given-names></name></person-group>. <article-title>Conventional Versus Giant Basal Cell Carcinoma, a Review of 57 Cases: Histologic Differences Contributing to Excessive Growth.</article-title> <source>Indian J Dermatol</source>. <year>2018</year>;<volume>63</volume>:<fpage>147</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.4103/ijd.IJD_165_17</pub-id><pub-id pub-id-type="pmid">29692457</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randle</surname><given-names>HW</given-names></name></person-group>. <article-title>Basal cell carcinoma. Identification and treatment of the high-risk patient.</article-title> <source>Dermatol Surg</source>. <year>1996</year>;<volume>22</volume>:<fpage>255</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/j.1524-4725.1996.tb00316.x</pub-id><pub-id pub-id-type="pmid">8599737</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Betti</surname><given-names>R</given-names></name><name><surname>Inselvini</surname><given-names>E</given-names></name><name><surname>Moneghini</surname><given-names>L</given-names></name><name><surname>Crosti</surname><given-names>C</given-names></name></person-group>. <article-title>Giant basal cell carcinomas: report of four cases and considerations.</article-title> <source>J Dermatol</source>. <year>1997</year>;<volume>24</volume>(<issue>5</issue>):<fpage>317</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1111/j.1346-8138.1997.tb02797.x</pub-id><pub-id pub-id-type="pmid">9198321</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arslan</surname><given-names>H</given-names></name><name><surname>G&#x00FC;zel</surname><given-names>MZ</given-names></name><name><surname>Cnar</surname><given-names>C</given-names></name></person-group>. <article-title>Treatment of giant basal cell carcinomas of the head and neck with aggressive resection and complex reconstruction.</article-title> <source>J Craniofac Surg</source>. <year>2012</year>;<volume>23</volume>:<fpage>1634</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/SCS.0b013e31825da652</pub-id><pub-id pub-id-type="pmid">23147292</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lackey</surname><given-names>PL</given-names></name><name><surname>Sargent</surname><given-names>LA</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Brzezienski</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>JW</given-names></name></person-group>. <article-title>Giant basal cell carcinoma surgical management and reconstructive challenges.</article-title> <source>Ann Plast Surg</source>. <year>2007</year>;<volume>58</volume>:<fpage>250</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1097/01.sap.0000250842.96272.37</pub-id><pub-id pub-id-type="pmid">17471127</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archontaki</surname><given-names>M</given-names></name><name><surname>Stavrianos</surname><given-names>SD</given-names></name><name><surname>Korkolis</surname><given-names>DP</given-names></name><name><surname>Arnogiannaki</surname><given-names>N</given-names></name><name><surname>Vassiliadis</surname><given-names>V</given-names></name><name><surname>Liapakis</surname><given-names>IE</given-names></name><etal/></person-group> <article-title>Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature.</article-title> <source>Anticancer Res</source>. <year>2009</year>;<volume>29</volume>(<issue>7</issue>):<fpage>2655</fpage>&#x2013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">19596942</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoccali</surname><given-names>G</given-names></name><name><surname>Pajand</surname><given-names>R</given-names></name><name><surname>Papa</surname><given-names>P</given-names></name><name><surname>Orsini</surname><given-names>G</given-names></name><name><surname>Lomartine</surname><given-names>N</given-names></name><name><surname>Guliani</surname><given-names>M</given-names></name></person-group>. <article-title>Giant basal cell carcinoma of the skin: literature review and personal experience.</article-title> <source>J Eur Acad Dermatol Venereol</source>. <year>2012</year>;<volume>26</volume>:<fpage>942</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-3083.2011.04427.x</pub-id><pub-id pub-id-type="pmid">22211959</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yazdani Abyaneh</surname><given-names>MA</given-names></name><name><surname>Engel</surname><given-names>P</given-names></name><name><surname>Slominski</surname><given-names>A</given-names></name><name><surname>Ragsdale</surname><given-names>B</given-names></name><name><surname>Agag</surname><given-names>R</given-names></name><name><surname>Cramer</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Giant Basal Cell Carcinomas Express Neuroactive Mediators and Show a High Growth Rate: A Case-Control Study and Meta-Analysis of Etiopathogenic and Prognostic Factors.</article-title> <source>Am J Dermatopathol</source>. <year>2017</year>;<volume>39</volume>(<issue>3</issue>):<fpage>189</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1097/DAD.0000000000000640</pub-id><pub-id pub-id-type="pmid">27759693</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wollina</surname><given-names>U</given-names></name><name><surname>Bayyoud</surname><given-names>Y</given-names></name><name><surname>Kr&#x00F6;nert</surname><given-names>C</given-names></name><name><surname>Nowak</surname><given-names>A</given-names></name></person-group>. <article-title>Giant epithelial malignancies (Basal cell carcinoma, squamous cell carcinoma): a series of 20 tumors from a single center.</article-title> <source>J Cutan Aesthet Surg</source>. <year>2012</year>;<volume>5</volume>:<fpage>12</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4103/0974-2077.94328</pub-id><pub-id pub-id-type="pmid">22557850</pub-id></mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manstein</surname><given-names>CH</given-names></name><name><surname>Gottlieb</surname><given-names>N</given-names></name><name><surname>Manstein</surname><given-names>ME</given-names></name><name><surname>Manstein</surname><given-names>G</given-names></name></person-group>. <article-title>Giant basal cell carcinoma: a series of seven T3 tumors without metastasis.</article-title> <source>Plast Reconstr Surg</source>. <year>2000</year>;<volume>106</volume>:<fpage>653</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/00006534-200009010-00021</pub-id><pub-id pub-id-type="pmid">10987474</pub-id></mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kokavec</surname><given-names>R</given-names></name><name><surname>Fedeles</surname><given-names>J</given-names></name></person-group>. <article-title>Giant basal cell carcinomas: a result of neglect?</article-title> <source>Acta Chir Plast</source>. <year>2004</year>;<volume>46</volume>:<fpage>67</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">15663105</pub-id></mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>R</given-names></name><name><surname>Campolmi</surname><given-names>P</given-names></name><name><surname>Giomi</surname><given-names>B</given-names></name><name><surname>Massi</surname><given-names>D</given-names></name><name><surname>Cappugi</surname><given-names>P</given-names></name></person-group>. <article-title>Gigant exophytic basal cell carcinoma treated with radiotherapy.</article-title> <source>J Eur Acad Dermatol Venereol</source>. <year>2002</year>;<volume>16</volume>:<fpage>374</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1046/j.1468-3083.2002.00571.x</pub-id><pub-id pub-id-type="pmid">12224695</pub-id></mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randle</surname><given-names>HW</given-names></name><name><surname>Roenigk</surname><given-names>RK</given-names></name><name><surname>Brodland</surname><given-names>DG</given-names></name></person-group>. <article-title>Gigant basal cell carcinoma (T3). Who is at risk?</article-title> <source>Cancer</source>. <year>1993</year>;<volume>72</volume>:<fpage>1624</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(19930901)72:5&lt;1624::AID-CNCR2820720522&gt;3.0.CO;2-D</pub-id><pub-id pub-id-type="pmid">8348493</pub-id></mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudit</surname><given-names>D</given-names></name><name><surname>Pham</surname><given-names>H</given-names></name><name><surname>Grecu</surname><given-names>T</given-names></name><name><surname>Hodgson</surname><given-names>C</given-names></name><name><surname>Grant</surname><given-names>ME</given-names></name><name><surname>Rashed</surname><given-names>AA</given-names></name><etal/></person-group> <article-title>Reappraisal of giant basal cell carcinoma: Clinical features and outcomes.</article-title> <source>J Plast Reconstr Aesthet Surg</source>. <year>2020</year>;<volume>73</volume>(<issue>1</issue>):<fpage>53</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjps.2019.06.029</pub-id><pub-id pub-id-type="pmid">31519500</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gualdi</surname><given-names>G</given-names></name><name><surname>Monari</surname><given-names>P</given-names></name><name><surname>Calzavara-Pinton</surname><given-names>P</given-names></name><name><surname>Caravello</surname><given-names>S</given-names></name><name><surname>Fantini</surname><given-names>F</given-names></name><name><surname>Bornacina</surname><given-names>C</given-names></name><etal/></person-group> <article-title>When basal cell carcinomas became giant: an Italian multicenter study.</article-title> <source>Int J Dermatol</source>. <year>2020</year>;<volume>59</volume>(<issue>3</issue>):<fpage>377</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/ijd.14728</pub-id><pub-id pub-id-type="pmid">31774173</pub-id></mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetzel</surname><given-names>M</given-names></name><name><surname>Strickley</surname><given-names>J</given-names></name><name><surname>Haeberle</surname><given-names>MT</given-names></name><name><surname>Brown</surname><given-names>TS</given-names></name></person-group>. <article-title>Depth of invasion of aggressive and nonaggressive basal cell carcinoma.</article-title> <source>J Clin Aesthet Dermatol</source>. <year>2019</year>;<volume>12</volume>:<fpage>12</fpage>&#x2013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">30988868</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leibovitch</surname><given-names>I</given-names></name><name><surname>Huilgol</surname><given-names>SC</given-names></name><name><surname>Selve</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>D</given-names></name><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Paver</surname><given-names>R</given-names></name></person-group>. <article-title>Basosquamous carcinoma: Treatment with Mohs micrograph surgery.</article-title> <source>Cancer</source>. <year>2005</year>;<volume>104</volume>:<fpage>170</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.21143</pub-id><pub-id pub-id-type="pmid">15929123</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piva de Freitas</surname><given-names>P</given-names></name><name><surname>Senna</surname><given-names>CG</given-names></name><name><surname>Tabai</surname><given-names>M</given-names></name><name><surname>Chone</surname><given-names>CT</given-names></name><name><surname>Altemani</surname><given-names>A</given-names></name></person-group>. <article-title>Metastatic Basal Cell Carcinoma: a rare manifestation of a common disease.</article-title> <source>Case Rep Med</source>. <year>2017</year>;<volume>2017</volume>:<elocation-id>8929745</elocation-id>. <pub-id pub-id-type="doi">10.1155/2017/8929745</pub-id><pub-id pub-id-type="pmid">29279714</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>SN</given-names></name><name><surname>Sahl</surname><given-names>W</given-names></name><name><surname>Lo</surname><given-names>JS</given-names></name><name><surname>Mohs</surname><given-names>FE</given-names></name><name><surname>Warner</surname><given-names>T</given-names></name><name><surname>Dekkinga</surname><given-names>JA</given-names></name><etal/></person-group> <article-title>Metastatic basal cell carcinoma. Report of five cases.</article-title> <source>Cancer</source>. <year>1994</year>;<volume>73</volume>(<issue>2</issue>):<fpage>328</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/1097-0142(19940115)73:2&lt;328::AID-CNCR2820730216&gt;3.0.CO;2-U</pub-id><pub-id pub-id-type="pmid">8293396</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ting</surname><given-names>PT</given-names></name><name><surname>Kasper</surname><given-names>R</given-names></name><name><surname>Arlette</surname><given-names>JP</given-names></name></person-group>. <article-title>Metastatic basal cell carcinoma: report of two cases and literature review.</article-title> <source>J Cutan Med Surg</source>. <year>2005</year>;<volume>9</volume>:<fpage>10</fpage>&#x2013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1177/120347540500900104</pub-id><pub-id pub-id-type="pmid">16208438</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>JS</given-names></name><name><surname>Snow</surname><given-names>SN</given-names></name><name><surname>Reizner</surname><given-names>GT</given-names></name><name><surname>Mohs</surname><given-names>FE</given-names></name><name><surname>Larson</surname><given-names>PO</given-names></name><name><surname>Hruza</surname><given-names>GJ</given-names></name></person-group>. <article-title>Metastatic basal cell carcinoma: report of twelve cases with a review of the literature.</article-title> <source>J Am Acad Dermatol</source>. <year>1991</year>;<volume>24</volume>:<fpage>715</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0190-9622(91)70108-E</pub-id><pub-id pub-id-type="pmid">1869642</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurian</surname><given-names>RR</given-names></name><name><surname>Di Palma</surname><given-names>S</given-names></name><name><surname>Barrett</surname><given-names>AW</given-names></name></person-group>. <article-title>Basal cell carcinoma metastatic to parotid gland.</article-title> <source>Head Neck Pathol</source>. <year>2014</year>;<volume>8</volume>:<fpage>349</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/s12105-013-0507-3</pub-id><pub-id pub-id-type="pmid">24234479</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BF</given-names></name><name><surname>Moore</surname><given-names>PJ</given-names></name><name><surname>Goepel</surname><given-names>JR</given-names></name><name><surname>Slater</surname><given-names>DN</given-names></name></person-group>. <article-title>Basosquamous carcinoma, a wolf in sheep&#x2019;s clothing? Report of 3 cases.</article-title> <source>Postgrad Med J</source>. <year>1989</year>;<volume>65</volume>(<issue>768</issue>):<fpage>750</fpage>&#x2013;<lpage>1</lpage>. <pub-id pub-id-type="doi">10.1136/pgmj.65.768.750</pub-id><pub-id pub-id-type="pmid">2616403</pub-id></mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Poletti</surname><given-names>E</given-names></name><name><surname>Crowson</surname><given-names>AN</given-names></name></person-group>. <article-title>Basosquamous carcinoma.</article-title> <source>J Am Acad Dermatol</source>. <year>2009</year>;<volume>60</volume>:<fpage>137</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaad.2008.09.036</pub-id><pub-id pub-id-type="pmid">19103364</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarallo</surname><given-names>M</given-names></name><name><surname>Cigna</surname><given-names>E</given-names></name><name><surname>Frati</surname><given-names>R</given-names></name><name><surname>Delfino</surname><given-names>S</given-names></name><name><surname>Innocenzi</surname><given-names>D</given-names></name><name><surname>Fama</surname><given-names>U</given-names></name><etal/></person-group> <article-title>Metatypical basal cell carcinoma: a clinical review.</article-title> <source>J Exp Clin Cancer Res</source>. <year>2008</year>;<volume>27</volume>(<issue>1</issue>):<fpage>65</fpage>. <pub-id pub-id-type="doi">10.1186/1756-9966-27-65</pub-id><pub-id pub-id-type="pmid">18992138</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mott</surname><given-names>SE</given-names></name><name><surname>Hunter</surname><given-names>WJ</given-names></name></person-group>. <article-title>Silva, Huerter CJ. Approach to management of giant basal cell carcinoma.</article-title> <source>Cutis</source>. <year>2017</year>;<volume>99</volume>:<fpage>356</fpage>&#x2013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">28632797</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rudi&#x0107;</surname><given-names>M</given-names></name><name><surname>Kranj&#x010D;ec</surname><given-names>Z</given-names></name><name><surname>Lisica-&#x0160;iki&#x0107;</surname><given-names>N</given-names></name><name><surname>Kova&#x010D;i&#x0107;</surname><given-names>M</given-names></name></person-group>. <article-title>Giant Basal Cell Carcinoma of the Forehead: a case report.</article-title> <source>Coll Antropol</source>. <year>2012</year>;<volume>36</volume>:<fpage>317</fpage>&#x2013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22816239</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maimaiti</surname><given-names>A</given-names></name><name><surname>Mijiti</surname><given-names>A</given-names></name><name><surname>Yarbag</surname><given-names>A</given-names></name><name><surname>Moming</surname><given-names>A</given-names></name></person-group>. <article-title>Giant basal cell carcinoma of the face: surgical management and challenges for reconstruction.</article-title> <source>J Laryngol Otol</source>. <year>2016</year>;<volume>130</volume>:<fpage>176</fpage>&#x2013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1017/S0022215115003333</pub-id><pub-id pub-id-type="pmid">26676100</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
